肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2015年
4期
238-242
,共5页
房新建%张磊%孟祥启%蒋华
房新建%張磊%孟祥啟%蔣華
방신건%장뢰%맹상계%장화
CD44st%癌,非小细胞肺%预后
CD44st%癌,非小細胞肺%預後
CD44st%암,비소세포폐%예후
CD44st%Carcinoma,non-small cell lung%Prognosis
目的 检测一种新CD44st基因mRNA在非小细胞肺癌(NSCLC)组织的表达并探讨其临床意义.方法 依据在乳腺癌耐药细胞株研究中发现的CD44st基因mRNA(Gene Bank NO.FJ216964)设计特异性引物序列,应用半定量反转录PCR(RT-PCR)方法、基因测序方法及实时荧光定量PCR(QRT-PCR)方法检测并验证CD44st基因mRNA在83例NSCLC患者(腺癌47例,鳞状细胞癌36例)癌组织及癌旁组织的表达,并分析其与临床病理学特征的关系.结果 NSCLC组织中,CD44stmRNA表达阳性53例(63.9％),癌旁组织中,均未见CD44st mRNA(P＜ 0.001).基因测序结果显示:CD44st基因mRNA序列与研究组在MCF-7/Adr细胞中发现的CD44st基因mRNA序列一致.CD44stmRNA表达与患者的分化程度及肿瘤大小无关(P＞ 0.05);CD44st mRNA在鳞状细胞癌组织中表达高于腺癌,与淋巴结转移及TNM分期相关(P＜0.05).CD44st mRNA低表达组患者2年内疾病进展或死亡率为45.2％(19/42),病情稳定率为54.8％(23/42),CD44st高表达组疾病进展或死亡率为68.3％(28/41),病情稳定率为31.7％(13/41),两组差异有统计学意义(P＜0.05).结论 CD44st基因mRNA在NSCLC组织中高表达与组织病理分类、淋巴结转移及肿瘤分期密切相关,并影响着患者的预后.针对该分子靶点的检测及治疗对于NSCLC患者可能是一种有益选择.
目的 檢測一種新CD44st基因mRNA在非小細胞肺癌(NSCLC)組織的錶達併探討其臨床意義.方法 依據在乳腺癌耐藥細胞株研究中髮現的CD44st基因mRNA(Gene Bank NO.FJ216964)設計特異性引物序列,應用半定量反轉錄PCR(RT-PCR)方法、基因測序方法及實時熒光定量PCR(QRT-PCR)方法檢測併驗證CD44st基因mRNA在83例NSCLC患者(腺癌47例,鱗狀細胞癌36例)癌組織及癌徬組織的錶達,併分析其與臨床病理學特徵的關繫.結果 NSCLC組織中,CD44stmRNA錶達暘性53例(63.9％),癌徬組織中,均未見CD44st mRNA(P＜ 0.001).基因測序結果顯示:CD44st基因mRNA序列與研究組在MCF-7/Adr細胞中髮現的CD44st基因mRNA序列一緻.CD44stmRNA錶達與患者的分化程度及腫瘤大小無關(P＞ 0.05);CD44st mRNA在鱗狀細胞癌組織中錶達高于腺癌,與淋巴結轉移及TNM分期相關(P＜0.05).CD44st mRNA低錶達組患者2年內疾病進展或死亡率為45.2％(19/42),病情穩定率為54.8％(23/42),CD44st高錶達組疾病進展或死亡率為68.3％(28/41),病情穩定率為31.7％(13/41),兩組差異有統計學意義(P＜0.05).結論 CD44st基因mRNA在NSCLC組織中高錶達與組織病理分類、淋巴結轉移及腫瘤分期密切相關,併影響著患者的預後.針對該分子靶點的檢測及治療對于NSCLC患者可能是一種有益選擇.
목적 검측일충신CD44st기인mRNA재비소세포폐암(NSCLC)조직적표체병탐토기림상의의.방법 의거재유선암내약세포주연구중발현적CD44st기인mRNA(Gene Bank NO.FJ216964)설계특이성인물서렬,응용반정량반전록PCR(RT-PCR)방법、기인측서방법급실시형광정량PCR(QRT-PCR)방법검측병험증CD44st기인mRNA재83례NSCLC환자(선암47례,린상세포암36례)암조직급암방조직적표체,병분석기여림상병이학특정적관계.결과 NSCLC조직중,CD44stmRNA표체양성53례(63.9％),암방조직중,균미견CD44st mRNA(P＜ 0.001).기인측서결과현시:CD44st기인mRNA서렬여연구조재MCF-7/Adr세포중발현적CD44st기인mRNA서렬일치.CD44stmRNA표체여환자적분화정도급종류대소무관(P＞ 0.05);CD44st mRNA재린상세포암조직중표체고우선암,여림파결전이급TNM분기상관(P＜0.05).CD44st mRNA저표체조환자2년내질병진전혹사망솔위45.2％(19/42),병정은정솔위54.8％(23/42),CD44st고표체조질병진전혹사망솔위68.3％(28/41),병정은정솔위31.7％(13/41),량조차이유통계학의의(P＜0.05).결론 CD44st기인mRNA재NSCLC조직중고표체여조직병리분류、림파결전이급종류분기밀절상관,병영향착환자적예후.침대해분자파점적검측급치료대우NSCLC환자가능시일충유익선택.
Objective To investigate the clinical significance of CD44st expression in non-small cell lung carcinoma (NSCLC).Methods Specific primers for the CD44st gene (Gene Bank NO.FJ216964) which was found in multidrug resistance cells were designed,and reverse transcription-polymerase chain reaction (RT-PCR),gene sequencing and real-time PCR were used to validate the expression of the CD44st in the tissues and cancer adjacent tissues of 83 NSCLC patients (47 cases of adenocarcinoma,36 cases of squamous carcinoma).The clinicopathologic features were analyzed by statistical analysis method.Results The positive expressive rate of CD44st gene mRNA in NSCLC tissue was 63.9 ％ (53/83) and the negative expressive rate was 36.1％ (30/83),which were more higher than those of cancer adjacent tissues (0/30,0 ％) (P ＜ 0.001).DNA sequencing results showed that the sequence of CD44st mRNA was consistent with the CD44st mRNA found in MCF-7/Adr cells in our previous study.Expression of CD44st was closely associated with pathological pattern,lymphatic metastasis and TNM staging in NSCLC (P ＜ 0.05),but not with tumor size and differentiated degree (P ＞ 0.05).The rates of two years disease progression and stable condition in the group of lower CD44st expression were 45.2 ％ (19/42) and 54.8 ％ (23/42),respectively,and the rates in the group of higher CD44st expression were 68.3 ％ (28/41) and 31.7 ％ (13/41),respectively (P ＜ 0.05).Conclusions The expression level of CD44st is closely related to pathological pattern,the lymph node metastasis and the TNM-staging in NSCLC patients,which seriously influences the prognosis of the NSCLC patients.Therefore,the detection and the therapy to this special target may be a beneficial choice for the prognostic prediction of NSCLC.
